Profile data is unavailable for this security.
About the company
Northwest Biotherapeutics, Inc. is a biotechnology company. The Company is focused on developing personalized immune therapies for cancer. It has developed a platform technology, DCVax, which uses activated dendritic cells to mobilize a patient's own immune system to attack their cancer. The Company's product line includes DCVax-L and DCVax-Direct. DCVax-L is designed to treat solid tumor cancers in which the tumors can be surgically removed. It has completed a 331-patient international Phase III trial of DCVax-L for Glioblastoma multiforme brain cancer (GBM). DCVax-Direct is designed to treat inoperable solid tumors. A 40-patient Phase I trial has been completed and includes treatment of a diverse range of more than a dozen types of cancers. Its platform technology, DCVax, is a personalized immune therapy that uses a patient’s own dendritic cells, or DCs, the master cells of the immune system, as the therapeutic agent. Its subsidiaries include Flaskworks LLC, NW Bio GmbH, and others.
- Revenue in USD (TTM)937.00k
- Net income in USD-91.22m
- Incorporated1998
- Employees25.00
- LocationNorthwest Biotherapeutics IncSUITE 800, 4800 MONTGOMERY LANEBETHESDA 20814United StatesUSA
- Phone+1 (240) 497-9024
- Fax+1 (302) 636-5454
- Websitehttps://nwbio.com/
More ▼
Mergers & acquisitions
| Acquired company | NWBO:QBB since announced | Transaction value |
|---|---|---|
| Advent Bioservices Ltd | -7.45% | -- |
Data delayed at least 15 minutes, as of Mar 05 2026 19:30 GMT.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aldeyra Therapeutics Inc | 0.00 | -33.85m | 312.65m | 8.00 | -- | 7.06 | -- | -- | -0.5637 | -0.5637 | 0.00 | 0.7355 | 0.00 | -- | -- | 0.00 | -38.32 | -33.16 | -51.97 | -37.60 | -- | -- | -- | -- | -- | -- | 0.2563 | -- | -- | -- | 39.40 | -- | -- | -- |
| Rezolute Inc | 0.00 | -84.23m | 313.89m | 71.00 | -- | 2.45 | -- | -- | -0.9239 | -0.9239 | 0.00 | 1.34 | 0.00 | -- | -- | 0.00 | -67.21 | -47.11 | -73.08 | -49.55 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -8.70 | -- | -- | -- |
| KALA BIO Inc | 0.00 | -35.84m | 314.68m | 38.00 | -- | -- | -- | -- | -5.94 | -5.94 | 0.00 | -1.17 | 0.00 | -- | -- | 0.00 | -90.62 | -61.19 | -316.35 | -75.37 | -- | -- | -- | -1,732.87 | -- | -12.71 | 1.44 | -- | -- | -- | 8.74 | -- | -31.05 | -- |
| Crescent Biopharma Inc | 0.00 | -55.96m | 316.63m | 4.00 | -- | 1.42 | -- | -- | -21.97 | -21.97 | 0.00 | 8.40 | 0.00 | -- | -- | 0.00 | -72.70 | -55.66 | -86.54 | -62.83 | -- | -- | -- | -2,068.09 | -- | -- | 0.00 | -- | -100.00 | -- | -2.66 | -- | -41.45 | -- |
| Protara Therapeutics Inc | 0.00 | -52.90m | 320.11m | 28.00 | -- | 1.81 | -- | -- | -1.43 | -1.43 | 0.00 | 3.43 | 0.00 | -- | -- | 0.00 | -44.32 | -35.06 | -48.05 | -36.43 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -10.33 | -- | 31.54 | -- |
| Cabaletta Bio Inc | 0.00 | -158.52m | 330.19m | 148.00 | -- | 2.37 | -- | -- | -2.51 | -2.51 | 0.00 | 1.45 | 0.00 | -- | -- | 0.00 | -80.43 | -40.80 | -97.39 | -43.86 | -- | -- | -- | -- | -- | -- | 0.1371 | -- | -- | -- | -71.21 | -- | 26.12 | -- |
| Nautilus Biotechnology Inc | 0.00 | -59.00m | 331.60m | 130.00 | -- | 2.11 | -- | -- | -0.4673 | -0.4673 | 0.00 | 1.24 | 0.00 | -- | -- | 0.00 | -27.20 | -21.03 | -28.21 | -21.55 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 16.64 | -- | 6.75 | -- |
| Foghorn Therapeutics Inc | 24.52m | -72.12m | 332.11m | 112.00 | -- | -- | -- | 13.55 | -1.15 | -1.15 | 0.3896 | -1.59 | 0.0955 | -- | -- | 218,910.70 | -28.10 | -28.66 | -38.84 | -33.19 | -- | -- | -294.16 | -596.97 | -- | -- | -- | -- | -33.83 | -- | 11.99 | -- | -1.32 | -- |
| Avalo Therapeutics Inc | 192.00k | -99.70m | 332.94m | 23.00 | -- | 3.58 | -- | 1,734.06 | -8.79 | -8.79 | 0.0169 | 5.14 | 0.0017 | -- | -- | 8,347.83 | -89.35 | -94.60 | -128.95 | -128.31 | 54.69 | 81.11 | -52,019.79 | -790.66 | -- | -9.83 | 0.0248 | -- | -77.08 | -42.05 | -11.37 | -- | -- | -- |
| Immuneering Corp | 0.00 | -62.50m | 333.83m | 54.00 | -- | 1.44 | -- | -- | -1.78 | -1.78 | 0.00 | 3.59 | 0.00 | -- | -- | 0.00 | -40.37 | -46.52 | -42.64 | -49.48 | -- | -- | -- | -4,578.95 | -- | -- | 0.00 | -- | -- | -- | -14.15 | -- | 32.83 | -- |
| Northwest Biotherapeutics Inc | 937.00k | -91.22m | 339.37m | 25.00 | -- | -- | -- | 362.19 | -0.0655 | -0.0655 | 0.0007 | -0.0627 | 0.0313 | -- | -- | 37,480.00 | -299.59 | -398.92 | -- | -- | -- | -- | -9,580.90 | -8,255.92 | -- | -6.69 | -- | -- | -28.47 | -10.53 | -32.34 | -- | 23.01 | -- |
| Relmada Therapeutics Inc | 0.00 | -56.17m | 349.80m | 17.00 | -- | 16.73 | -- | -- | -1.80 | -1.80 | 0.00 | 0.2852 | 0.00 | -- | -- | 0.00 | -159.13 | -77.37 | -195.99 | -84.69 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 19.04 | -- | -- | -- |
| Sutro Biopharma Inc | 105.65m | -216.77m | 350.17m | 178.00 | -- | -- | -- | 3.31 | -25.98 | -25.98 | 12.61 | -10.25 | 0.3194 | -- | 19.98 | 340,793.60 | -65.54 | -31.36 | -94.60 | -37.63 | -- | -- | -205.18 | -152.29 | -- | -- | -- | -- | -59.64 | 7.74 | -112.99 | -- | -2.30 | -- |
| NovaBridge Biosciences | 0.00 | -26.33m | 358.56m | 32.00 | -- | 1.38 | -- | -- | -0.3045 | -0.2827 | 0.00 | 2.25 | 0.00 | -- | -- | 0.00 | -10.32 | -26.21 | -10.92 | -30.19 | -- | -- | -- | -389.26 | -- | -- | 0.00 | -- | -100.00 | -- | 39.56 | -- | -51.41 | -- |
| Candel Therapeutics Inc | 0.00 | -22.76m | 362.56m | 38.00 | -- | 3.39 | -- | -- | -0.5591 | -0.5591 | 0.00 | 1.46 | 0.00 | -- | -- | 0.00 | -39.54 | -51.34 | -51.19 | -60.61 | -- | -- | -- | -44,190.40 | -- | -- | 0.0609 | -- | -- | -- | -45.44 | -- | -36.83 | -- |
| Organogenesis Holdings Inc | 564.17m | 15.85m | 369.20m | 854.00 | 30.85 | 1.21 | 10.72 | 0.6544 | 0.093 | 0.093 | 4.30 | 3.42 | 1.03 | 4.93 | 3.45 | 660,619.40 | 6.75 | 6.67 | 8.06 | 8.08 | 75.62 | 75.86 | 6.56 | 6.39 | 3.32 | -- | 0.0487 | 0.00 | 17.04 | 10.77 | 2,236.82 | 3.04 | -4.35 | -- |
Data as of Mar 05 2026. Currency figures normalised to Northwest Biotherapeutics Inc's reporting currency: US Dollar USD
0.05%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Moloney Securities Asset Management LLCas of 30 Sep 2025 | 534.71k | 0.04% |
| VSM Wealth Advisory LLCas of 31 Dec 2025 | 80.57k | 0.01% |
| Opus Capital Group LLCas of 31 Dec 2025 | 60.15k | 0.00% |
| Ethos Financial Group LLCas of 31 Dec 2025 | 28.35k | 0.00% |
| Williams Jones Wealth Management LLCas of 31 Dec 2025 | 27.00k | 0.00% |
| Advisors Management Group, Inc.as of 31 Dec 2025 | 10.27k | 0.00% |
| British & American Investment Trust Plc (Invt Mgmt)as of 30 Jun 2025 | 5.71k | 0.00% |
| Coston, McIsaac & Partners, Inc.as of 31 Dec 2025 | 1.00k | 0.00% |
| Hantz Financial Services, Inc.as of 31 Dec 2025 | 250.00 | 0.00% |
| KLCM Advisors, Inc.as of 31 Dec 2025 | 0.00 | 0.00% |
More ▼
Data from 30 Jun 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
